Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 04, 2024 09:45 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces $87.4 Million Private Placement

SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
February 26, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Participate at Upcoming Investor Conferences

SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
February 12, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
February 01, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform

Signs a World-Wide Exclusive License with Stony Brook University for a Novel Platform that can Enhance Radionuclide TargetingReceives up to $2.4M NIH Grant to Develop Differentiated Antibody-based...
January 22, 2024 16:05 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Closing of $69.0 Million Public Offering and $20.8 Million Private Placement

SEATTLE, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
January 18, 2024 07:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

SEATTLE, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
January 17, 2024 16:05 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Proposed Public Offering

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment...
January 17, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Commences Recruitment for Second Dose Escalation Cohorts in Clinical Studies of Two Lead Programs: [(212)Pb]VMT-α-NET and [(212)Pb]VMT01

SEATTLE, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), today announced that it began patient recruitment for the second dosing cohorts (Cohort 2) in...
January 09, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Enters into Strategic Agreements with Lantheus Including Equity Investment, Co-Development Options, and Expansion of Manufacturing Capability

Lantheus will have the option to negotiate an exclusive license to Perspective Therapeutics’ Pb212-VMT-α-NETLantheus will have the option to co-fund and negotiate an exclusive license for certain...
January 05, 2024 08:00 ET | Source: Perspective Therapeutics, Inc.

Perspective Therapeutics Announces Exclusive License Agreement with Mayo Clinic for New Radiopharmaceutical Platform for Prostate Cancer Treatment

Mayo Clinic’s PSMA Alpha-PET DoubLET platform allows for imaging and targeted therapy with alpha and/or beta-particle radiopharmaceutical therapy (RPT) using a novel 64/67Cu and 203/212Pb double...